IP Library › Granted Patent US 9,884,912
Granted Patent B2
US 9,884,912 · App. 14/546,074 · Granted Feb 6, 2018

Antibodies to IL-6 and use thereof

Inventors: Leon F. Garcia-Martinez (Woodinville, WA); Anne Elisabeth Carvalho Jensen (Wenatchee, WA); Katie Olson Anderson (Kirkland, WA); Benjamin H. Dutzar (Seattle, WA); Ethan Wayne Ojala (Snohomish, WA); Brian R. Kovacevich (Snohomish, WA); John A. Latham (Seattle, WA); Jeffrey T. L. Smith (Bellevue, WA)
Assignee: ALDERBIO HOLDINGS LLC
C07K16/248A61K2039/505C07K2317/24C07K2317/34C07K2317/41C07K2317/56C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,912
App. No.
14/546,074
Granted
Feb 6, 2018
Kind
B2
Abstract

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Claims (13)

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a heavy chain polypeptide or variable heavy chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 20, 702, 706 and 709; and a nucleic acid sequence encoding a light chain polypeptide or variable light chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 18, 19, 657, 658, 704 and 708.

2. The polynucleotide of claim 1 where yeast or human preferred codons are used.

3. A vector comprising the isolated polynucleotide of claim 1 .

4. A recombinant cell which comprises the isolated polynucleotide of claim 1 .

5. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:701 or SEQ ID NO:705 and the heavy chain polypeptide is encoded by SEQ ID NO:703 or 707.

6. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:701 and the heavy chain polypeptide is encoded by SEQ ID NO:703.

7. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:705 and the heavy chain polypeptide is encoded by SEQ ID NO:707.

8. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:705 and the heavy chain polypeptide is encoded by SEQ ID NO:703.

9. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:701 and the heavy chain polypeptide is encoded by SEQ ID NO:707.

10. An isolated polynucleotide comprising a nucleic acid sequence encoding an amino acid sequence selected from SEQ ID NOS: 2, 3, 18, 19, 20, 702, 704, 706, 708 and 709.

11. The isolated polynucleotide of claim 10 where yeast or human preferred codons are used.

12. A vector comprising the isolated polynucleotide of claim 10 .

13. A recombinant cell comprising the isolated polynucleotide of claim 10 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2020
From: H. LUNDBECK A/S
To: VITAERIS INC.
Reel/Frame 053496/0319 →
CHANGE OF NAME Recorded Jun 23, 2020
From: ALDER BIOPHARMACEUTICALS, INC.
To: LUNDBECK SEATTLE BIOPHARMACEUTICALS, INC.
Reel/Frame 053020/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2020
From: LUNDBECK SEATTLE BIOPHARMACEUTICALS, INC
To: H. LUNDBECK A/S
Reel/Frame 053020/0205 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2015
From: BRISTOL-MYERS SQUIBB COMPANY
To: ALDERBIO HOLDINGS LLC
Reel/Frame 034777/0728 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2014
From: BRISTOL-MYERS SQUIBB COMPANY
To: ALDERBIO HOLDINGS LLC
Reel/Frame 034491/0663 →
Continuity (21)
Division 13277390 · Oct 20, 2011
Division 12391717 · Feb 24, 2009
Continuation In Part 12323066 · Nov 25, 2008
Continuation In Part 12153612 · May 21, 2008
Continuation In Part 12153611 · May 21, 2008
Continuation In Part 12124723 · May 21, 2008
Continuation In Part 12323147 · Nov 25, 2008
Continuation In Part 12153612
Continuation In Part 12323194 · Nov 25, 2008
Continuation In Part 12153612
Continuation In Part 12366567 · Feb 5, 2009
Continuation In Part 12323066
Continuation In Part 12323194
Continuation In Part 12323147
Continuation In Part 12153611
Continuation In Part 12124723
Continuation In Part 12153611
Continuation In Part 12124723
Provisional Application 60924550 · May 21, 2007
Provisional Application 60924551 · May 21, 2007
Related Publication 20150132224A1 · May 14, 2015